|
A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia
Donald J. Birkett,
Andrew S. Mitchell and
Peter McManus
The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Walker and S. Hall
NICE guidance on rheumatoid arthritis: Implications and challenges for rheumatologists
Rheumatology,
December 23, 2009;
(2009)
kep415v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Harris, S. R. Hill, G. Chin, J. J. Li, and E. Walkom
The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004
Med Decis Making,
September 1, 2008;
28(5):
713 - 722.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Lopert and S. Rosenbaum
What Is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia
J. Law Med. Ethics,
December 1, 2007;
35(4):
643 - 656.
[PDF]
|
|
|
|
|
|
|
D. A. Henry, S. R. Hill, and A. Harris
Drug Prices and Value for Money: The Australian Pharmaceutical Benefits Scheme
JAMA,
November 23, 2005;
294(20):
2630 - 2632.
[Full Text]
[PDF]
|
|
|
|
